Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 4, 2009, Pages

  Nakhoul, Farid M ^a,d   Miller Lotan, Rachel ^b   Awad, Hoda ^b   Asleh, Rabea ^b   Jad, Kheir ^b   Nakhoul, Nakhoul ^c   Asaf, Roy ^b   Abu Saleh, Niroz ^b   Levy, Andrew P ^b  

^a Rambam Health Care Campus   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Diabetic nephropathy; Hyperglycemia

Indexed keywords

ACTIN; ALPHA TOCOPHEROL; COLLAGEN TYPE 4; CREATININE; HAPTOGLOBIN; IRON;

ALBUMINURIA; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE LOCUS; GENOTYPE; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY STRUCTURE; MORPHOMETRICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PROTECTION; SMOOTH MUSCLE; TRANSGENIC MOUSE;

EID: 65949087452     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90655.2008     Document Type: Article

References (49)

1. Asleh R, Marsh S, Shiltruck M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92: 1193-1200, 2003. (Pubitemid 36723646)
2. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype and diabetes dependent differences in iron mediated oxidative stress in vitro and in vivo. Circ Res 96: 435-441, 2005. (Pubitemid 40354537)
3. Awadallah S, Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios 101: 145-150, 2000.
4. Awadallah S, Hamad M. A study of Haptoglobin phenotypes in patients with chronic renal failure. Ann Clin Biochem 40: 680-683, 2003. (Pubitemid 37421715)
5. Bessa SS, Hamdy SM, Ali EM. Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: an Egyptian study. Eur J Int Med 18: 489-495, 2007.
6. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297: 842-857, 2007. (Pubitemid 46333949)
7. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin dependent diabetes mellitus. N Engl J Med 330: 15-28, 1994. (Pubitemid 24018611)
8. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 12: 189-261, 1982.
9. Burbea Z, Nakhoul F, Rosenberg S, Zoabi R, Skorecki K, Hochberg I, Lotan R, Benchetrit S, Weisgarten J, Knecht A, Tovbin D, Levy NS, Levy AP. Haptoglobin phenotype role in end-stage kidney. Nephron Exp Nephrol 97: 71-76, 2004. (Pubitemid 41315696)
10. Chowdhury TA, Kumar S, Barnett AH, Bain SC. Nephropathy in type I diabetes: the role of genetic factors. Diabet Med 12: 1059-1067, 1995. (Pubitemid 26009948)
11. Chowdhury TA, Kumar S, Barnett AH, Bain SC. Genetic determinants of diabetic nephropathy. Clin Sci 96: 221-230, 1999. (Pubitemid 29129172)
12. Conway BR, Savage DA, Brady HR, Maxwell AP. Association between haptoglobin gene variants and diabetic nephropathy: haptoglobin polymorphism in nephropathy susceptibility. Nephron Exp Nephrol 105: e75-e79, 2007.
13. Costacou T, Ferrell RE, Orchard T. Haptoglobin genotype and renal disease progression in type I diabetes (Abstract). Diabetologia 51: 5473-5474, 2007. (Pubitemid 47451523)
14. Dunn SR, Qi Z, Bottinger EP, Breyer MD, Sharma K. Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65: 1959-1967, 1967.
15. Gaede P, Poulsen HE, Parving HH, Pedersen O. Double blind randomized study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients. Diabet Med 18: 756-760, 2001. (Pubitemid 32238954)
16. Gburek J, Verroust PJ, Willnow TE, Fyfe JC, Nowacki W, Jacobsen C, Moestrup SK, Christiansen EI. Megalin and cubulin are endocytotic receptors involved in renal clearance of hemoglobin. J Am Soc Nephrol 13: 423-430, 2002. (Pubitemid 34110430)
17. Giannini C, Lombardo F, Curro F, Pomillo M, Bucciarelli T, Chiarelli F, Mohn A. Effects of high dose vitamin E supplementation on oxidative stress and microalbuminuria in young adult patients with childhood onset type I diabetes mellitus. Diabetes Metab Res Rev 23: 539-546, 2007. (Pubitemid 350018027)
18. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, van Ypersole de Monnier VM, Witztum JL, Kurokawa K. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100: 2995-3004, 1997.
19. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes 47: 821-830, 1998. (Pubitemid 28201814)
20. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 55: 1-28, 1999. (Pubitemid 29004235)
21. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper M, Jandeleit-Dahm KAM. Accelerated nephropathy in diabetic apolipoprotein E-knockout mouse: role of advanced glycation end product. J Am Soc Nephrol 15: 2125-2138, 2004. (Pubitemid 39276622)
22. Levy AP, Roguin A, Marsh S, Nakhoul FM, Herer P, Hochberg I, Skorecki K. Haptoglobin phenotype and vascular complications in diabetes. N Engl J Med 343: 969-970, 2000.
23. Levy AP. Complication-resistant patients. In: Perspectives and Advances in Diagnosis and Treatment, edited by Shafrir E and Raz I. London: Martin Dunitz, 2003, p. 55-68.
24. Levy AP, Gerstein H, Lotan R, Ratner R, McQueen M, Lonn E, Pogue J. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 27: 2767, 2004. (Pubitemid 39441487)
25. Levy AP. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther 112: 501-512, 2006.
26. Levy AP, Levy JE, Kalet-Litman Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 27: 134-140, 2007. (Pubitemid 46360390)
27. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101: 106-110, 2007. (Pubitemid 47094629)
28. Marre M. Genetics and prediction of complications in type I diabetes. Diab Care 22S: B53-B58, 1999.
29. Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98: 3693-3698, 2001.
30. Miller-Lotan R, Herskowitz Y, Kalet-Litman S, Nakhoul F, Aronson D, Zoabi R, Asaf R, Ben-Izhak O, Sabo E, Lim SK, Baumann H, Berger FG, Levy AP. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 21: 332-337, 2005. (Pubitemid 40945954)
31. Miller-Lotan R, Miller B, Aronson D, Asaf R, Nakhoul F, Levy AP. Retinal capillary basement membrane thickness in diabetic mice geneti- cally modified at the haptoglobin locus. Diabetes Metab Res Rev 23: 152-156, 2007. (Pubitemid 46306437)
32. Miller ER, Barriuso RP, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all cause mortality. Ann Intern Med 142: 37-46, 2005. (Pubitemid 40066212)
33. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alsheik J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective, double-blinded clinical trial. Arterioscler Thromb Vasc Biol 28: 341-347, 2008.
34. Nakhoul FM, Zoabi R, Kantor Y, Zoabi M, Hochberg I, Leibu R, Miller B, Skorecki K, Levy AP. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 44: 602-604, 2001. (Pubitemid 32411276)
35. Nankivell BJ, Tay YC, Boadle RA, Harris DC. Lysosomal iron accumulation in diabetic nephropathy. Ren Fail 16: 367-381, 1994.
36. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000. (Pubitemid 30212409)
37. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39: 1116-1124, 1990.
38. Parving HH, Hommel E, Smidt UM. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes mellitus. BMJ 296: 156-160, 1988.
39. Parving HH, Tarnow L, Rossing P. Genetics of diabetic nephropathy. J Am Soc Nephrol 7: 2509-2517, 1996. (Pubitemid 27469556)
40. Rossing P, Rossing K, Jacobsen P, Parving HH. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 44: 739-743, 1995.
41. Ruiz J. Diabetes mellitus and late complications: influence of the genetic factors. Diabet Med 23S2: 57-63, 1997.
42. Steinberg D, Witztum JL. Is the oxidation modification hypothesis relevant to human atherosclerosis: do the antioxidant trials conducted to date refute the hypothesis? Circulation 105: 2107-2111, 2002.
43. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, Uchida K, Izuhara Y, Yagame M, Sakai H, Kurokawa K. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10: 822-832, 1999. (Pubitemid 29149533)
44. Suzuki D, Miyata T. Carbonyl stress in the pathogenesis of diabetic nephropathy. Intern Med 38: 309-314, 1999.
45. UK Prospective Diabetes Study Group. Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, south asian and afro-caribbean patients with type 2 diabetes. Diabetes Care 21: 1271-1277, 1998.
46. Venerando B, Fiorilli A, Croci G, Tringali C, Goi G, Mazzanti L, Curatola G, Segalini G, Massaccesi L, Lombardo A, Tettamanti G. Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients. Blood 99: 1064-1070, 2002. (Pubitemid 34525572)
47. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160, 2000.
48. Zerbini G, Gabellini D, Maestroni S, Maestroni A. Early renal dysfunctions in type 1 diabetes and pathogenesis of diabetic nephropathy. J Nephrol 20: S19-S22, 2007.
49. Zhang H, Saha J, Byun J, Schin ML, Lorenz M, Kennedy RT, Kretzler M, Feldman EL, Pennathur S, Brosius FC III. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 295: F1071-F1081, 2008.